MicroRNA Profiling of Breast Cancer using miRCURY™ LNA Arrays
Poster Jan 18, 2007
Thomas Litman, Mikkel Nørholm, Christian Glue, Nina Stahlberg, Nana Jacobsen, Jens Eriksen, Inge M Svane, Henrik Flyger, Eva Balslev, Carsten Alsb and Søren Møller
• MicroRNAs (miRNAs) comprise a recently identified class of small, non-protein-coding regulatory molecules that play important roles in many physiologic and pathologic processes, including differentiation, viral infection, and oncogenesis.
• In cancer, abnormal miRNA expression suggests that these molecules may serve as valuable diagnostic and prognostic molecular signatures.
• To study the global miRNA expression profiles in breast cancer, we use the miRCURY™ LNA Array platform, which is based on locked nucleic acid (LNA)-modified capture probes that have uniquely high affinities for miRNA.
• For quantitative validation of new miRNA biomarkers, we apply a novel miRCURY™ LNA qPCR assay.
Despite the developments in conventional PCR, the complexity of multiplex Real Time PCR is still limited due to the lack of sufficient detection channels. To achieve high-end multiplexing capacity on standard Real Time PCR machines, Anapa Biotech has developed the MeltPlex® technology (see box on right).READ MORE